This case series looks at the actions taken by NGOs, local campaigners and the Indian government, against Roche over its patent for a breast cancer drug “Trastuzumab”, otherwise known as “Herceptin”, Herceptin was an expensive but highly effective treatment for some types of breast cancer and campaigners were vocal in arguing that in emerging markets, such as India, it was beyond the means of the majority of the population. Case B covers the period and actions from January 2013 to mid-2014. Sensing that it would not receive a renewal of its patent protection from the Indian government, in August 2013, Roche decided not to pursue its patent in India. The government fast-tracked local companies to produce biosimilars. In January 2014, the local biosimilar was launched onto the marketplace but it was only 25% less expensive than Herceptin. In an unusual twist, a month later, the Delhi High Court granted Roche an injunction against the generic manufacturers comparing their products to Herceptin in marketing campaigns.
Explore an IMD white paper with Microsoft and EqualVoice, launched at Davos, addressing GenAI bias risks and offering survey insights and recommendations.
Last year saw a nearly 60% surge in phishing attacks. While systemic defenses against such threats offer valuable protection, they are not enough. Enhance your resistance to phishing by taking this short quiz. Last year saw a nearly 60% surge in p...
Honda and Nissan's $58bn merger aims to compete with China's EV dominance, but risks include cultural clashes, overlapping markets, and uncertain innovation outcomes.
Explore top books, websites, and podcasts recommended by IMD expert Jim Pulcrano for anyone venturing into or exploring venture capital, from entrepreneurs to investors.
David Michels, CFO at Kinder Morgan, a US energy infrastructure company, explores how rapid AI and data center growth have quickly reshaped energy demand
Corporate DE&I is not simply a question of fairness. Implemented successfully, it pays off for both the company and society in general. Here’s how it’s done. Corporate DE&I is not simply a question of fairness. Implemented successfully, it pays of...
Corporate DE&I is not simply a question of fairness. Implemented successfully, it pays off for both the company and society in general. Here's how it's done.
At Davos' SDG Tent, panelists urged a shift from financial metrics to valuing natural, social, and human capital for sustainable prosperity. Julia Binder
Explore how perceptions of leadership evolved. Anand Narasimhan delves into archetypes, offering insights to shape your responsible leadership approach.
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications